Master Alliance Provisions Guide (MAPGuide)

All Agreements

(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
Agreement
Academic Institution - Company, Research Collaboration Agreement
2016
Academic institution
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.equitable-access.redacted-collaboration-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 1220
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-2/
            [children] => 
        )

    [business-model.roles-responsibilities.academic-institution-company-research-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4090
            [provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.redacted-collaboration-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1248
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-6/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.redacted-collaboration-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 1233
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-4/
            [children] => 
        )

    [information-sharing.publication-of-results.redacted-collaboration-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 1233
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-4/
            [children] => 
        )

    [information-sharing.technology-transfer.redacted-collaboration-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 1238
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-5/
            [children] => 
        )

    [ip-ownership.exploitation-results.academic-institution-company-research-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 4092
            [provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.redacted-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 1150
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.redacted-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 1150
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.academic-institution-company-research-collaboration-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 4093
            [provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-4/
            [children] => 
        )

    [ip-ownership.use-background-ip.academic-institution-company-research-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 4092
            [provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-3/
            [children] => 
        )

    [liability.indemnity.academic-institution-company-research-collaboration-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4095
            [provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-6/
            [children] => 
        )

    [liability.insurance.academic-institution-company-research-collaboration-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4098
            [provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-9/
            [children] => 
        )

    [liability.warranties.academic-institution-company-research-collaboration-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4094
            [provision_permalink] => https://ghiaa.org/provision_document/academic-institution-company-research-collaboration-agreement-5/
            [children] => 
        )

    [term-and-termination.effect-of-termination.redacted-collaboration-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 1282
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-7/
            [children] => 
        )

    [term-and-termination.term-of-agreement.redacted-collaboration-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1282
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-7/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.redacted-collaboration-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1282
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-7/
            [children] => 
        )

)
AUTM Model Inter-Institutional Research Collaboration Agreement
2015
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [business-model.benefit-revenue-sharing.autm-model-inter-institutional-research-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 4105
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-inter-institutional-research-collaboration-agreement/
            [children] => 
        )

    [business-model.royalties-and-payments.autm-model-inter-institutional-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3698
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-inter-institutional-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.autm-model-iia-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1243
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.autm-model-inter-institutional-research-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4113
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-inter-institutional-research-collaboration-agreement-3/
            [children] => 
        )

    [ip-ownership.exploitation-results.autm-model-iia-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 1182
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-3/
            [children] => 
        )

    [ip-ownership.protection-results.autm-model-iia] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1164
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia/
            [children] => 
        )

    [liability.indemnity.autm-model-iia-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1273
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-6/
            [children] => 
        )

    [liability.warranties.lambert-agreement-d-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 1259
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-9/
            [children] => 
        )

    [term-and-termination.effect-of-termination.autm-model-inter-institutional-research-collaboration-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4112
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-inter-institutional-research-collaboration-agreement-2/
            [children] => 
        )

    [term-and-termination.term-of-agreement.autm-model-iia-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1280
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-7/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.autm-model-iia-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1280
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-7/
            [children] => 
        )

)
AUTM Preliminary Patent Management Agreement
2013
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
  • No Issues
BARDA - Moderna, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [access-to-medicines.ensuring-continuity.barda-moderna-covid-19-vaccine-development-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 3758
            [provision_permalink] => https://ghiaa.org/provision_document/barda-moderna-covid-19-vaccine-development-agreement-2/
            [children] => 
        )

    [business-model.roles-responsibilities.moderna-barda-contract-for-development-of-mrna-vaccine-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 2444
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-5/
            [children] => 
        )

    [information-sharing.confidentiality.moderna-barda-contract-for-development-of-mrna-vaccine-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 2443
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.barda-moderna-covid-19-vaccine-development-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3764
            [provision_permalink] => https://ghiaa.org/provision_document/barda-moderna-covid-19-vaccine-development-agreement-3/
            [children] => 
        )

    [ip-ownership.exploitation-results.moderna-barda-contract-for-development-of-mrna-vaccine-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 2442
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-3/
            [children] => 
        )

    [ip-ownership.ownership-results.moderna-barda-contract-for-development-of-mrna-vaccine-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 2442
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-3/
            [children] => 
        )

    [ip-ownership.protection-results.moderna-barda-contract-for-development-of-mrna-vaccine-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 2442
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-3/
            [children] => 
        )

    [liability.indemnity.moderna-barda-contract-for-development-of-mrna-vaccine-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 2441
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-barda-contract-for-development-of-mrna-vaccine-2/
            [children] => 
        )

)
Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.pricing.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 4214
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3/
            [children] => 
        )

    [business-model.regulatory-strategy.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 4223
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14/
            [children] => 
        )

    [business-model.roles-responsibilities.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4222
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13/
            [children] => 
        )

    [business-model.royalties-and-payments.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4214
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3/
            [children] => 
        )

    [business-model.supply-purchase-of-products.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 4213
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5/
            [children] => 
        )

    [information-sharing.confidentiality.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4212
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4221
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 4209
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 4209
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 4210
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 4209
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement/
            [children] => 
        )

    [liability.indemnity.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4215
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6/
            [children] => 
        )

    [liability.insurance.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4216
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7/
            [children] => 
        )

    [liability.warranties.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4217
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4220
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11/
            [children] => 
        )

    [term-and-termination.term-of-agreement.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4218
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4219
            [provision_permalink] => https://ghiaa.org/provision_document/biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10/
            [children] => 
        )

)
BMGF - Arsanis RSV Monoclonal Antibodies Funding Agreement
2017
Funder
Industry
Drug
Preclinical
Array
(
    [access-to-medicines.ensuring-continuity.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 4681
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2/
            [children] => 
        )

    [access-to-medicines.equitable-access.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4680
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement/
            [children] => 
        )

    [business-model.royalties-and-payments.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4684
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-5/
            [children] => 
        )

    [information-sharing.confidentiality.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4682
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4691
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-11/
            [children] => 
        )

    [information-sharing.publication-of-results.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 4683
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-4/
            [children] => 
        )

    [liability.indemnity.what-are-the-mechanisms-to-limit-exposure-to-additional-payments-or-expenses] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4685
            [provision_permalink] => https://ghiaa.org/provision_document/what-are-the-mechanisms-to-limit-exposure-to-additional-payments-or-expenses/
            [children] => 
        )

    [liability.insurance.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4686
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-6/
            [children] => 
        )

    [liability.warranties.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4687
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-7/
            [children] => 
        )

    [term-and-termination.effect-of-termination.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4690
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4688
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-8/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4689
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-9/
            [children] => 
        )

)
BMGF - Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
2017
Funder
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 4695
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement/
            [children] => 
        )

    [access-to-medicines.equitable-access.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4696
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-2/
            [children] => 
        )

    [access-to-medicines.pricing.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 4697
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 4697
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-3/
            [children] => 
        )

    [business-model.roles-responsibilities.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4704
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-10/
            [children] => 
        )

    [information-sharing.confidentiality.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4698
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4699
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5/
            [children] => 
        )

    [information-sharing.publication-of-results.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 4699
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-5/
            [children] => 
        )

    [liability.indemnity.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4700
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-6/
            [children] => 
        )

    [liability.warranties.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4701
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-7/
            [children] => 
        )

    [term-and-termination.effect-of-termination.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4703
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4702
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement-8/
            [children] => 
        )

)
BMGF - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
2020
Funder
Industry
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.equitable-access.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 3375
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments/
            [children] => 
        )

    [information-sharing.confidentiality.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3379
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3377
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-3/
            [children] => 
        )

    [ip-ownership.exploitation-results.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 3378
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4/
            [children] => 
        )

    [ip-ownership.ownership-results.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 3378
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4/
            [children] => 
        )

    [term-and-termination.term-of-agreement.bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3376
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-2/
            [children] => 
        )

)
BMGF - CureVac, Global Access Commitments Agreement
2015
Funder
Industry
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.ensuring-continuity.bmgf-curevac-global-access-commitments-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 3357
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-8/
            [children] => 
        )

    [access-to-medicines.equitable-access.bmgf-curevac-global-access-commitments-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 3335
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement/
            [children] => 
        )

    [access-to-medicines.pricing.bmgf-curevac-global-access-commitments-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 3345
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-2/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.bmgf-curevac-global-access-commitments-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 3355
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-7/
            [children] => 
        )

    [business-model.royalties-and-payments.bmgf-curevac-global-access-commitments-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3346
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-3/
            [children] => 
        )

    [information-sharing.confidentiality.bmgf-curevac-global-access-commitments-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3365
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-12/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.bmgf-curevac-global-access-commitments-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3353
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-6/
            [children] => 
        )

    [information-sharing.publication-of-results.bmgf-curevac-global-access-commitments-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 3350
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-results.bmgf-curevac-global-access-commitments-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 3347
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-4/
            [children] => 
        )

    [ip-ownership.protection-results.bmgf-curevac-global-access-commitments-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3347
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-4/
            [children] => 
        )

    [liability.indemnity.bmgf-curevac-global-access-commitments-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3367
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-13/
            [children] => 
        )

    [liability.insurance.bmgf-curevac-global-access-commitments-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 3362
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-11/
            [children] => 
        )

    [liability.warranties.bmgf-curevac-global-access-commitments-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3359
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.bmgf-curevac-global-access-commitments-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3358
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.bmgf-curevac-global-access-commitments-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3369
            [provision_permalink] => https://ghiaa.org/provision_document/bmgf-curevac-global-access-commitments-agreement-14/
            [children] => 
        )

)
Boston University Startup Exclusive License Template
2012
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [ip-ownership.use-background-ip.bu-startup-exclusive-license] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 1127
            [provision_permalink] => https://ghiaa.org/provision_document/bu-startup-exclusive-license/
            [children] => 
        )

    [liability.indemnity.bu-startup-exclusive-license-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1272
            [provision_permalink] => https://ghiaa.org/provision_document/bu-startup-exclusive-license-2/
            [children] => 
        )

)
CARB-X Research Subaward Agreement (for-profit)
2019
Funder
Industry
Drug
Preclinical
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.ensuring-continuity.carb-x-research-subaward-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 1187
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-2/
            [children] => 
        )

    [access-to-medicines.equitable-access.carb-x-research-subaward-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4516
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement/
            [children] => 
        )

    [information-sharing.publication-of-results.carb-x-research-subaward-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 1218
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-3/
            [children] => 
        )

    [ip-ownership.exploitation-results.carb-x-research-subaward-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 1187
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-2/
            [children] => 
        )

)
CAVD Data & Materials Sharing Agreement
2006
Academic institution
Funder
Government
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.gates-foundation-data-materials-sharing-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1254
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-data-materials-sharing-agreement-4/
            [children] => 
        )

    [ip-ownership.exploitation-results.cavd-data-materials-sharing-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 1134
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-results.cavd-data-materials-sharing-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 1134
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-2/
            [children] => 
        )

)
Cellscript - BioNTech mRNA Technology Patent Sublicense
2016
Industry
Vaccine
Preclinical
Array
(
    [business-model.roles-responsibilities.cellscript-biontech-mrna-technology-patent-sublicense-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4490
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-11/
            [children] => 
        )

    [business-model.royalties-and-payments.cellscript-biontech-mrna-technology-patent-sublicense-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4483
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-4/
            [children] => 
        )

    [information-sharing.confidentiality.cellscript-biontech-mrna-technology-patent-sublicense-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4482
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cellscript-biontech-mrna-technology-patent-sublicense-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4489
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-10/
            [children] => 
        )

    [ip-ownership.protection-results.cellscript-biontech-mrna-technology-patent-sublicense-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 4481
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.cellscript-biontech-mrna-technology-patent-sublicense] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 4469
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense/
            [children] => 
        )

    [liability.indemnity.cellscript-biontech-mrna-technology-patent-sublicense-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4484
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-5/
            [children] => 
        )

    [liability.insurance.cellscript-biontech-mrna-technology-patent-sublicense-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4491
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-12/
            [children] => 
        )

    [liability.warranties.cellscript-biontech-mrna-technology-patent-sublicense-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4485
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-6/
            [children] => 
        )

    [term-and-termination.effect-of-termination.cellscript-biontech-mrna-technology-patent-sublicense-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4488
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-9/
            [children] => 
        )

    [term-and-termination.term-of-agreement.cellscript-biontech-mrna-technology-patent-sublicense-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4486
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-7/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.cellscript-biontech-mrna-technology-patent-sublicense-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4487
            [provision_permalink] => https://ghiaa.org/provision_document/cellscript-biontech-mrna-technology-patent-sublicense-8/
            [children] => 
        )

)
CEPI - CureVac, Framework Partnering Agreement
2019
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.cepi-curevac-framework-partnering-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 3329
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-11/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.cepi-curevac-framework-partnering-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 3327
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-9/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.cepi-curevac-framework-partnering-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 4580
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-3/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.13-commercial-benefits-arising-from-commercial-use-13-3-use-of-product-in-affected-territory-only-cepi-intends-to-take-reasonable-efforts-to-ensure-that-the-products-will-be-utilized-in-the-affected] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 3321
            [provision_permalink] => https://ghiaa.org/provision_document/13-commercial-benefits-arising-from-commercial-use-13-3-use-of-product-in-affected-territory-only-cepi-intends-to-take-reasonable-efforts-to-ensure-that-the-products-will-be-utilized-in-the-affected/
            [children] => 
        )

    [business-model.regulatory-strategy.cepi-curevac-framework-partnering-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3318
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-4/
            [children] => 
        )

    [business-model.roles-responsibilities.cepi-curevac-framework-partnering-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3323
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-6/
            [children] => 
        )

    [business-model.royalties-and-payments.cepi-curevac-framework-partnering-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3315
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.cepi-curevac-framework-partnering-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3338
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-16/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cepi-curevac-framework-partnering-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3316
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-2/
            [children] => 
        )

    [information-sharing.publication-of-results.cepi-curevac-framework-partnering-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 3326
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-8/
            [children] => 
        )

    [ip-ownership.exploitation-results.cepi-curevac-framework-partnering-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 3337
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-15/
            [children] => 
        )

    [ip-ownership.ownership-results.cepi-curevac-framework-partnering-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 3331
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-13/
            [children] => 
        )

    [ip-ownership.protection-results.cepi-curevac-framework-partnering-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3330
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-12/
            [children] => 
        )

    [ip-ownership.protection-results.cepi-curevac-framework-partnering-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3336
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-14/
            [children] => 
        )

    [liability.indemnity.cepi-curevac-framework-partnering-agreement-19] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3341
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-19/
            [children] => 
        )

    [liability.insurance.cepi-curevac-framework-partnering-agreement-20] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 3342
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-20/
            [children] => 
        )

    [liability.warranties.cepi-curevac-framework-partnering-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3339
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-17/
            [children] => 
        )

    [term-and-termination.effect-of-termination.cepi-curevac-framework-partnering-agreement-22] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3344
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-22/
            [children] => 
        )

    [term-and-termination.term-of-agreement.cepi-curevac-framework-partnering-agreement-21] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3343
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-21/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.cepi-curevac-framework-partnering-agreement-21] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3343
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-curevac-framework-partnering-agreement-21/
            [children] => 
        )

)
CEPI - Dynavax, COVID-19 Material Reservation Agreement
2021
Funder
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.equitable-access.cepi-dynavax-covid-19-material-reservation-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4128
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement/
            [children] => 
        )

    [access-to-medicines.pricing.cepi-dynavax-covid-19-material-reservation-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 4129
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-2/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.cepi-dynavax-covid-19-material-reservation-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 4129
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-2/
            [children] => 
        )

    [business-model.regulatory-strategy.cepi-dynavax-covid-19-material-reservation-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 4141
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-13/
            [children] => 
        )

    [business-model.roles-responsibilities.cepi-dynavax-covid-19-material-reservation-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4140
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-12/
            [children] => 
        )

    [business-model.royalties-and-payments.cepi-dynavax-covid-19-material-reservation-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4133
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-5/
            [children] => 
        )

    [business-model.supply-purchase-of-products.cepi-dynavax-covid-19-material-reservation-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 4131
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-4/
            [children] => 
        )

    [information-sharing.confidentiality.cepi-dynavax-covid-19-material-reservation-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4130
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cepi-dynavax-covid-19-material-reservation-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4139
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-11/
            [children] => 
        )

    [liability.indemnity.cepi-dynavax-covid-19-material-reservation-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4134
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-6/
            [children] => 
        )

    [liability.warranties.cepi-dynavax-covid-19-material-reservation-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4135
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-7/
            [children] => 
        )

    [term-and-termination.effect-of-termination.cepi-dynavax-covid-19-material-reservation-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4138
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.cepi-dynavax-covid-19-material-reservation-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4136
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-8/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.cepi-dynavax-covid-19-material-reservation-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4137
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-dynavax-covid-19-material-reservation-agreement-9/
            [children] => 
        )

)
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Vaccine
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 2890
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5/
            [children] => 
        )

    [access-to-medicines.equitable-access.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 2892
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 2890
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5/
            [children] => 
        )

    [access-to-medicines.pricing.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 2892
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 2892
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.cepi-novavax-covid-19-vaccine-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 4204
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-4/
            [children] => 
        )

    [business-model.regulatory-strategy.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 2889
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4/
            [children] => 
        )

    [business-model.roles-responsibilities.cepi-novavax-covid-19-vaccine-funding-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4200
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-2/
            [children] => 
        )

    [business-model.royalties-and-payments.cepi-novavax-covid-19-vaccine-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3493
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.cepi-novavax-covid-19-vaccine-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4205
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cepi-novavax-covid-19-vaccine-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4201
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-novavax-covid-19-vaccine-funding-agreement-3/
            [children] => 
        )

    [information-sharing.publication-of-results.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 2893
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 2885
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 2885
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 2885
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement/
            [children] => 
        )

    [ip-ownership.use-background-ip.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 2885
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement/
            [children] => 
        )

    [liability.indemnity.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 2908
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9/
            [children] => 
        )

    [liability.insurance.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 2908
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9/
            [children] => 
        )

    [liability.warranties.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2907
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 2909
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 2909
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 2909
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10/
            [children] => 
        )

)
CEPI - Valneva, Chikungunya Vaccine Funding Agreement
2019
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.ensuring-continuity.cepi-valneva-chikungunya-vaccine-funding-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 3748
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-10/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.cepi-valneva-chikungunya-vaccine-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 3724
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-3/
            [children] => 
        )

    [access-to-medicines.pricing.cepi-valneva-chikungunya-vaccine-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 3726
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-5/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.cepi-valneva-chikungunya-vaccine-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 3726
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-5/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.cepi-valneva-chikungunya-vaccine-funding-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 3747
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-9/
            [children] => 
        )

    [business-model.roles-responsibilities.cepi-valneva-chikungunya-vaccine-funding-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3756
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-17/
            [children] => 
        )

    [business-model.royalties-and-payments.cepi-valneva-chikungunya-vaccine-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3722
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.cepi-valneva-chikungunya-vaccine-funding-agreement-18] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3757
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-18/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cepi-valneva-chikungunya-vaccine-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3725
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-4/
            [children] => 
        )

    [information-sharing.publication-of-results.cepi-valneva-chikungunya-vaccine-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 3744
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-7/
            [children] => 
        )

    [ip-ownership.ownership-results.cepi-valneva-chikungunya-vaccine-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 3743
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-6/
            [children] => 
        )

    [ip-ownership.protection-results.cepi-valneva-chikungunya-vaccine-funding-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3746
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-8/
            [children] => 
        )

    [liability.indemnity.cepi-valneva-chikungunya-vaccine-funding-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3751
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-12/
            [children] => 
        )

    [liability.insurance.cepi-valneva-chikungunya-vaccine-funding-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 3753
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-14/
            [children] => 
        )

    [liability.warranties.cepi-valneva-chikungunya-vaccine-funding-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3749
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-11/
            [children] => 
        )

    [term-and-termination.effect-of-termination.cepi-valneva-chikungunya-vaccine-funding-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3755
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-16/
            [children] => 
        )

    [term-and-termination.term-of-agreement.cepi-valneva-chikungunya-vaccine-funding-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3754
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-15/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.cepi-valneva-chikungunya-vaccine-funding-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3754
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-valneva-chikungunya-vaccine-funding-agreement-15/
            [children] => 
        )

)
CEPI CfP3i Vaccine Funding Agreement Template
2018
Funder
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.ensuring-continuity.cepi-cfp3i-template-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 1205
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-4/
            [children] => 
        )

    [access-to-medicines.equitable-access.cepi-cfp3i-template-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 1202
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-6/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.cepi-cfp3i-template-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 1204
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-5/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.cepi-cfp3i-template-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 1203
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cepi-cfp3i-template-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3736
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement/
            [children] => 
        )

    [information-sharing.publication-of-results.cepi-cfpi3-template-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 1221
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfpi3-template-funding-agreement/
            [children] => 
        )

    [information-sharing.technology-transfer.cepi-cfp3i-template-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 3736
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.cepi-cfp3i-template-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 1159
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-7/
            [children] => 
        )

    [ip-ownership.protection-results.cepi-cfp3i-template-funding-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 996
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-8/
            [children] => 
        )

)
CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
2021
Government
Multilateral organization
Diagnostic
Commercialization
Array
(
    [access-to-medicines.pricing.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 4796
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement/
            [children] => 
        )

    [business-model.roles-responsibilities.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4806
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9/
            [children] => 
        )

    [business-model.royalties-and-payments.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4798
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3/
            [children] => 
        )

    [information-sharing.confidentiality.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4800
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4808
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11/
            [children] => 
        )

    [information-sharing.technology-transfer.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 4801
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5/
            [children] => 
        )

    [ip-ownership.protection-results.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 4797
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 4796
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement/
            [children] => 
        )

    [liability.warranties.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4802
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6/
            [children] => 
        )

    [term-and-termination.effect-of-termination.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4807
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4804
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4805
            [provision_permalink] => https://ghiaa.org/provision_document/csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8/
            [children] => 
        )

)
CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
2021
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [business-model.regulatory-strategy.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 4002
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3/
            [children] => 
        )

    [business-model.roles-responsibilities.curevac-and-gsk-collaboration-and-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4009
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-and-gsk-collaboration-and-license-agreement-2/
            [children] => 
        )

    [business-model.royalties-and-payments.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4004
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5/
            [children] => 
        )

    [business-model.supply-purchase-of-products.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 4007
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8/
            [children] => 
        )

    [information-sharing.confidentiality.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4013
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4003
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4/
            [children] => 
        )

    [information-sharing.publication-of-results.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 4014
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13/
            [children] => 
        )

    [information-sharing.technology-transfer.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 4006
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7/
            [children] => 
        )

    [ip-ownership.exploitation-results.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 4001
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 4011
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10/
            [children] => 
        )

    [ip-ownership.ownership-results.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 4012
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-11/
            [children] => 
        )

    [ip-ownership.protection-results.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3997
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement/
            [children] => 
        )

    [ip-ownership.use-background-ip.curevac-and-gsk-collaboration-and-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 3819
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-and-gsk-collaboration-and-license-agreement/
            [children] => 
        )

    [liability.indemnity.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4016
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15/
            [children] => 
        )

    [liability.insurance.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4024
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22/
            [children] => 
        )

    [liability.warranties.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4017
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16/
            [children] => 
        )

    [term-and-termination.effect-of-termination.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4022
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20/
            [children] => 
        )

    [term-and-termination.term-of-agreement.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4020
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4021
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19/
            [children] => 
        )

)
Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [business-model.regulatory-strategy.pfizer-biontech-dominican-republic-binding-term-sheet-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3120
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-2/
            [children] => 
        )

    [business-model.roles-responsibilities.pfizer-biontech-dominican-republic-binding-term-sheet-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3125
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-7/
            [children] => 
        )

    [business-model.supply-purchase-of-products.pfizer-biontech-dominican-republic-binding-term-sheet-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3121
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-3/
            [children] => 
        )

    [information-sharing.confidentiality.pfizer-biontech-dominican-republic-binding-term-sheet-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3122
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.pfizer-biontech-dominican-republic-binding-term-sheet-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3127
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-9/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.pfizer-biontech-dominican-republic-binding-term-sheet] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 3119
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet/
            [children] => 
        )

    [liability.indemnity.pfizer-biontech-dominican-republic-binding-term-sheet-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3123
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-5/
            [children] => 
        )

    [liability.warranties.pfizer-biontech-dominican-republic-binding-term-sheet-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3123
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-5/
            [children] => 
        )

    [liability.warranties.pfizer-biontech-dominican-republic-binding-term-sheet-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3124
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-6/
            [children] => 
        )

    [term-and-termination.term-of-agreement.pfizer-biontech-dominican-republic-binding-term-sheet-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3126
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-biontech-dominican-republic-binding-term-sheet-8/
            [children] => 
        )

)
EDCTP2 Policy on Clinical Trials Registration, Publication, and Data Sharing
2018
Funder
Device
Diagnostic
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [information-sharing.publication-of-results.edctp2-policy-on-clinical-trials-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 1215
            [provision_permalink] => https://ghiaa.org/provision_document/edctp2-policy-on-clinical-trials-2/
            [children] => 
        )

)
European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.donation.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 271
            [slug] => donation
            [title] => Donation
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Donation
            [provision_id] => 2540
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11/
            [children] => 
        )

    [access-to-medicines.ensuring-continuity.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 2544
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8/
            [children] => 
        )

    [business-model.regulatory-strategy.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 2541
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10/
            [children] => 
        )

    [business-model.roles-responsibilities.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 2545
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7/
            [children] => 
        )

    [business-model.royalties-and-payments.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 2543
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12/
            [children] => 
        )

    [business-model.supply-purchase-of-products.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 2540
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11/
            [children] => 
        )

    [information-sharing.confidentiality.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 2549
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 2541
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10/
            [children] => 
        )

    [ip-ownership.exploitation-results.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 2544
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8/
            [children] => 
        )

    [ip-ownership.ownership-results.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 2544
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8/
            [children] => 
        )

    [liability.indemnity.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 2547
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5/
            [children] => 
        )

    [liability.warranties.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2542
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9/
            [children] => 
        )

    [term-and-termination.effect-of-termination.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 2553
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

    [term-and-termination.term-of-agreement.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 2553
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 2553
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

)
European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.donation.curevac-ec-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 271
            [slug] => donation
            [title] => Donation
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Donation
            [provision_id] => 2471
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.curevac-ec-covid-19-vaccine-advance-purchase-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 2470
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-14/
            [children] => 
        )

    [business-model.regulatory-strategy.curevac-ec-covid-19-vaccine-advance-purchase-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 2473
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-12/
            [children] => 
        )

    [business-model.roles-responsibilities.curevac-ec-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 2477
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-8/
            [children] => 
        )

    [business-model.royalties-and-payments.curevac-ec-covid-19-vaccine-advance-purchase-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 2475
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-10/
            [children] => 
        )

    [business-model.supply-purchase-of-products.curevac-ec-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 2471
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.curevac-ec-covid-19-vaccine-advance-purchase-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 2481
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.european-commission-curevac-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3741
            [provision_permalink] => https://ghiaa.org/provision_document/european-commission-curevac-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [ip-ownership.exploitation-results.curevac-ec-covid-19-vaccine-advance-purchase-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 2476
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-9/
            [children] => 
        )

    [ip-ownership.ownership-results.curevac-ec-covid-19-vaccine-advance-purchase-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 2476
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-9/
            [children] => 
        )

    [liability.indemnity.curevac-ec-covid-19-vaccine-advance-purchase-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 2479
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-6/
            [children] => 
        )

    [liability.warranties.curevac-ec-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2474
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-11/
            [children] => 
        )

    [term-and-termination.effect-of-termination.european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4058
            [provision_permalink] => https://ghiaa.org/provision_document/european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.curevac-ec-covid-19-vaccine-advance-purchase-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 2482
            [provision_permalink] => https://ghiaa.org/provision_document/curevac-ec-covid-19-vaccine-advance-purchase-agreement-3/
            [children] => 
        )

)
Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.territory-access-commitments.fiocruz-astrazeneca-covid-19-technological-order-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 3420
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement/
            [children] => 
        )

    [business-model.regulatory-strategy.fiocruz-astrazeneca-covid-19-technological-order-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3424
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-4/
            [children] => 
        )

    [business-model.roles-responsibilities.fiocruz-astrazeneca-covid-19-technological-order-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3427
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-6/
            [children] => 
        )

    [business-model.royalties-and-payments.fiocruz-astrazeneca-covid-19-technological-order-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3433
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-10/
            [children] => 
        )

    [information-sharing.confidentiality.fiocruz-astrazeneca-covid-19-technological-order-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3434
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-11/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.fiocruz-astrazeneca-covid-19-technological-order-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3428
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-7/
            [children] => 
        )

    [information-sharing.technology-transfer.fiocruz-astrazeneca-covid-19-technological-order-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 3421
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.fiocruz-astrazeneca-covid-19-technological-order-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 3422
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-3/
            [children] => 
        )

    [liability.indemnity.fiocruz-astrazeneca-covid-19-technological-order-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3436
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-13/
            [children] => 
        )

    [liability.warranties.fiocruz-astrazeneca-covid-19-technological-order-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3430
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.fiocruz-astrazeneca-covid-19-technological-order-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4601
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-12/
            [children] => 
        )

    [term-and-termination.term-of-agreement.fiocruz-astrazeneca-covid-19-technological-order-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3426
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-5/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.fiocruz-astrazeneca-covid-19-technological-order-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3431
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-technological-order-agreement-9/
            [children] => 
        )

)
Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
2021
Government
Industry
Vaccine
Commercialization
Array
(
    [access-to-medicines.donation.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 271
            [slug] => donation
            [title] => Donation
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Donation
            [provision_id] => 3849
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5/
            [children] => 
        )

    [access-to-medicines.pricing.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 3848
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4/
            [children] => 
        )

    [business-model.regulatory-strategy.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3863
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19/
            [children] => 
        )

    [business-model.roles-responsibilities.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3861
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17/
            [children] => 
        )

    [business-model.supply-purchase-of-products.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3855
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11/
            [children] => 
        )

    [information-sharing.confidentiality.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3851
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3856
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12/
            [children] => 
        )

    [information-sharing.publication-of-results.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 3852
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8/
            [children] => 
        )

    [information-sharing.technology-transfer.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 3854
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10/
            [children] => 
        )

    [ip-ownership.exploitation-results.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 3847
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-results.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 3847
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3/
            [children] => 
        )

    [ip-ownership.protection-results.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3846
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 3845
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement/
            [children] => 
        )

    [liability.warranties.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3857
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13/
            [children] => 
        )

    [term-and-termination.effect-of-termination.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3860
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16/
            [children] => 
        )

    [term-and-termination.term-of-agreement.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3858
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3859
            [provision_permalink] => https://ghiaa.org/provision_document/fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15/
            [children] => 
        )

)
Funder Development Partnering Agreement Template
2018
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.ensuring-continuity.funder-development-partnering-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 1201
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-8/
            [children] => 
        )

    [access-to-medicines.equitable-access.funder-development-partnering-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 1199
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-7/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.funder-development-partnering-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 1198
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-6/
            [children] => 
        )

    [access-to-medicines.pricing.funder-development-partnering-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 1199
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-7/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.funder-development-partnering-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 1199
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-7/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.funder-development-partnering-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit sharing
            [provision_id] => 1200
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-9/
            [children] => 
        )

    [ip-ownership.exploitation-results.funder-development-partnering-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 1184
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-results.funder-development-partnering-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 1158
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-2/
            [children] => 
        )

    [ip-ownership.protection-results.funder-development-partnering-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1139
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.funder-development-partnering-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1170
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-3/
            [children] => 
        )

    [ip-ownership.use-background-ip.funder-development-partnering-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 1139
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement/
            [children] => 
        )

    [liability.indemnity.funder-development-partnering-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1274
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-10/
            [children] => 
        )

)
Gates Foundation Sample Grant Terms & Conditions
2019
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.ensuring-continuity.gates-global-access-commitment-and-humanitarian-license] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 1206
            [provision_permalink] => https://ghiaa.org/provision_document/gates-global-access-commitment-and-humanitarian-license/
            [children] => 
        )

    [access-to-medicines.equitable-access.gates-foundation-sample-grant-terms-conditions] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4519
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-sample-grant-terms-conditions/
            [children] => 
        )

    [access-to-medicines.equitable-access.gates-global-access-commitment-and-humanitarian-license] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 1206
            [provision_permalink] => https://ghiaa.org/provision_document/gates-global-access-commitment-and-humanitarian-license/
            [children] => 
        )

    [information-sharing.confidentiality.gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1395
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2/
            [children] => 
        )

    [information-sharing.publication-of-results.gates-foundation-sample-terms-conditions-for-project-support-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 1394
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-sample-terms-conditions-for-project-support-grant-agreement/
            [children] => 
        )

)
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 4150
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3/
            [children] => 
        )

    [access-to-medicines.equitable-access.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4147
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15/
            [children] => 
        )

    [access-to-medicines.pricing.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 4149
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 4148
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13/
            [children] => 
        )

    [business-model.regulatory-strategy.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 4161
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14/
            [children] => 
        )

    [business-model.roles-responsibilities.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4159
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12/
            [children] => 
        )

    [business-model.royalties-and-payments.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4149
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2/
            [children] => 
        )

    [business-model.supply-purchase-of-products.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 4148
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13/
            [children] => 
        )

    [information-sharing.confidentiality.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4151
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4152
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 4146
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 4146
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [ip-ownership.use-background-ip.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 4146
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement/
            [children] => 
        )

    [liability.indemnity.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4153
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6/
            [children] => 
        )

    [liability.insurance.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4154
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7/
            [children] => 
        )

    [liability.warranties.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4155
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4158
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11/
            [children] => 
        )

    [term-and-termination.term-of-agreement.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4156
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4157
            [provision_permalink] => https://ghiaa.org/provision_document/gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10/
            [children] => 
        )

)
Gilead - Indian Generic Manufacturers, HCV License Agreement
2014
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [business-model.royalties-and-payments.gilead-indian-generic-manufacturers-hcv-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3691
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-indian-generic-manufacturers-hcv-license-agreement-2/
            [children] => 
        )

    [information-sharing.technology-transfer.gilead-indian-generic-manufacturers-hcv-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 3694
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-indian-generic-manufacturers-hcv-license-agreement-4/
            [children] => 
        )

    [ip-ownership.exploitation-results.gilead-hcv-license-agreement-with-indian-generic-manufacturers-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 1145
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-2/
            [children] => 
        )

    [ip-ownership.ownership-results.gilead-hcv-license-agreement-with-indian-generic-manufacturers-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 1145
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-2/
            [children] => 
        )

    [ip-ownership.protection-results.gilead-hcv-license-agreement-with-indian-generic-manufacturers-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1145
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-2/
            [children] => 
        )

    [ip-ownership.protection-results.gilead-indian-generic-manufacturers-hcv-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3692
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-indian-generic-manufacturers-hcv-license-agreement-3/
            [children] => 
        )

    [ip-ownership.use-background-ip.gilead-hcv-license-agreement-with-indian-generic-manufacturers] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 1137
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers/
            [children] => 
        )

    [liability.indemnity.gilead-indian-generic-manufacturers-hcv-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3689
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-indian-generic-manufacturers-hcv-license-agreement/
            [children] => 
        )

    [liability.insurance.gilead-hcv-license-agreement-with-indian-generic-manufacturers-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 1264
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-3/
            [children] => 
        )

)
IMI 1 Model Grant Agreement
2011
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [ip-ownership.exploitation-results.imi-1-model-grant-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 1171
            [provision_permalink] => https://ghiaa.org/provision_document/imi-1-model-grant-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.imi-1-model-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 1111
            [provision_permalink] => https://ghiaa.org/provision_document/imi-1-model-grant-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.imi-1-model-grant-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 1147
            [provision_permalink] => https://ghiaa.org/provision_document/imi-1-model-grant-agreement-2/
            [children] => 
        )

)
IMI 2 JU Model Consortium Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.imi-2-joint-undertaking-model-consortium-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1245
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-5/
            [children] => 
        )

    [information-sharing.technology-transfer.imi-2-joint-undertaking-model-consortium-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 1237
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-4/
            [children] => 
        )

    [ip-ownership.exploitation-results.1305] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 1305
            [provision_permalink] => https://ghiaa.org/provision_document/1305/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.imi-2joint-undertaking-model-consortium-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 1309
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2joint-undertaking-model-consortium-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.imi-2-joint-undertaking-model-consortium-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 1304
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-9/
            [children] => 
        )

    [ip-ownership.protection-results.imi-2-joint-undertaking-model-consortium-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1166
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.imi-2-joint-undertaking-model-consortium-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 1132
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement/
            [children] => 
        )

    [liability.indemnity.imi-2-joint-undertaking-model-consortium-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1261
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-7/
            [children] => 
        )

    [liability.indemnity.imi-2-joint-undertaking-model-consortium-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1266
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-8/
            [children] => 
        )

)
IMI 2 Model Grant Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.imi-2-model-grant-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1253
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-8/
            [children] => 
        )

    [information-sharing.publication-of-results.imi-2-model-grant-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 1211
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-6/
            [children] => 
        )

    [ip-ownership.exploitation-results.imi-2-model-grant-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 1178
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.imi-2-model-grant-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 1308
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-12/
            [children] => 
        )

    [ip-ownership.ownership-results.imi-2-model-grant-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 1303
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-10/
            [children] => 
        )

    [ip-ownership.protection-results.imi-2-model-grant-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1165
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-3/
            [children] => 
        )

    [ip-ownership.use-background-ip.imi-2-model-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 1128
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement/
            [children] => 
        )

    [liability.indemnity.imi-2-model-grant-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1268
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-9/
            [children] => 
        )

)
Israel - Pfizer, Epidemiological Evidence Collaboration Agreement
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [business-model.roles-responsibilities.2867] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 2867
            [provision_permalink] => https://ghiaa.org/provision_document/2867/
            [children] => 
        )

    [business-model.royalties-and-payments.2867] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 2867
            [provision_permalink] => https://ghiaa.org/provision_document/2867/
            [children] => 
        )

    [information-sharing.confidentiality.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 2869
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.2867] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 2867
            [provision_permalink] => https://ghiaa.org/provision_document/2867/
            [children] => 
        )

    [information-sharing.publication-of-results.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 2873
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 2872
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-results.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 2872
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5/
            [children] => 
        )

    [liability.warranties.israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2870
            [provision_permalink] => https://ghiaa.org/provision_document/israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4/
            [children] => 
        )

)
Lambert Toolkit, Consortium Agreement D Template
2019
Academic institution
Industry
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.lambert-agreement-d-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1239
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-5/
            [children] => 
        )

    [information-sharing.publication-of-results.lambert-agreement-d-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 1214
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-14/
            [children] => 
        )

    [ip-ownership.exploitation-results.lambert-agreement-d-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 1177
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-3/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.lambert-agreement-d] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 1107
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d/
            [children] => 
        )

    [ip-ownership.ownership-results.lambert-agreement-d-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 1141
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-2/
            [children] => 
        )

    [ip-ownership.protection-results.lambert-agreement-d-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1141
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.lambert-agreement-d-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 1113
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-15/
            [children] => 
        )

    [liability.indemnity.lambert-agreement-d-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1262
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-10/
            [children] => 
        )

    [liability.warranties.lambert-agreement-d-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 1258
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-8/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.lambert-agreement-d-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1281
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-12/
            [children] => 
        )

)
Merck - Bioprotection Systems Corp., Ebola Vaccine License & Collaboration Agreement
2014
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [information-sharing.confidentiality.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1242
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6/
            [children] => 
        )

    [information-sharing.technology-transfer.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 1235
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4/
            [children] => 
        )

    [ip-ownership.exploitation-results.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 1162
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 1112
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation/
            [children] => 
        )

    [ip-ownership.ownership-results.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 1162
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3/
            [children] => 
        )

    [ip-ownership.use-background-ip.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 1140
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2/
            [children] => 
        )

    [liability.indemnity.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1267
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7/
            [children] => 
        )

    [liability.indemnity.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1276
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 1287
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1285
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1285
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9/
            [children] => 
        )

)
Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
2020
Industry
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [business-model.regulatory-strategy.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3886
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16/
            [children] => 
        )

    [business-model.roles-responsibilities.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3884
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14/
            [children] => 
        )

    [business-model.royalties-and-payments.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3876
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6/
            [children] => 
        )

    [business-model.supply-purchase-of-products.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3875
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5/
            [children] => 
        )

    [information-sharing.confidentiality.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3873
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4/
            [children] => 
        )

    [information-sharing.technology-transfer.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 3874
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2/
            [children] => 
        )

    [ip-ownership.exploitation-results.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 3869
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 3869
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17/
            [children] => 
        )

    [ip-ownership.ownership-results.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 3869
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17/
            [children] => 
        )

    [ip-ownership.protection-results.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3870
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement/
            [children] => 
        )

    [ip-ownership.use-background-ip.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 3869
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17/
            [children] => 
        )

    [liability.indemnity.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3877
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7/
            [children] => 
        )

    [liability.insurance.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 3878
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8/
            [children] => 
        )

    [liability.warranties.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3880
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10/
            [children] => 
        )

    [term-and-termination.effect-of-termination.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3883
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13/
            [children] => 
        )

    [term-and-termination.term-of-agreement.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3881
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3882
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12/
            [children] => 
        )

)
MPP - AbbVie, HIV Antiretroviral License Agreement
2016
Industry
Multilateral organization
Drug
Commercialization
Array
(
    [ip-ownership.use-background-ip.mpps-license-agreement-with-abbvie] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 1118
            [provision_permalink] => https://ghiaa.org/provision_document/mpps-license-agreement-with-abbvie/
            [children] => 
        )

)
MPP - AbbVie, HIV Antiretroviral Sublicense Agreement
2014
Industry
Multilateral organization
Drug
Commercialization
Array
(
    [ip-ownership.exploitation-results.mpp-license-agreement-with-abbvie] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 1183
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-abbvie/
            [children] => 
        )

    [ip-ownership.use-background-ip.mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 1125
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2/
            [children] => 
        )

    [liability.indemnity.mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1313
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3/
            [children] => 
        )

)
MPP - BMS - Aurobindo, Daclatasvir Sublicense & Tech Transfer Agreement
2016
Industry
Multilateral organization
Drug
Commercialization
Array
(
    [access-to-medicines.pricing.mpp-license-agreement-with-bms-aurobindo-pharma-ltd] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 1122
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-bms-aurobindo-pharma-ltd/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.mpp-license-agreement-with-bms-aurobindo-pharma-ltd] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 1122
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-bms-aurobindo-pharma-ltd/
            [children] => 
        )

    [information-sharing.technology-transfer.mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 1229
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2/
            [children] => 
        )

)
MPP - BMS Sublicense & Tech Transfer Agreement
2017
Industry
Multilateral organization
Drug
Commercialization
Array
(
    [business-model.regulatory-strategy.mpp-bms-sublicense-tech-transfer-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3914
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-bms-sublicense-tech-transfer-agreement/
            [children] => 
        )

    [ip-ownership.use-background-ip.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 1124
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement/
            [children] => 
        )

    [liability.indemnity.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1314
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2/
            [children] => 
        )

    [liability.insurance.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 1314
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2/
            [children] => 
        )

    [term-and-termination.term-of-agreement.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1124
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement/
            [children] => 
        )

)
MPP - Gilead, TDF License Agreement
2011
Industry
Multilateral organization
Drug
Commercialization
Array
(
    [information-sharing.confidentiality.mpp-license-agreement-with-gilead-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1249
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-4/
            [children] => 
        )

    [information-sharing.technology-transfer.mpp-license-agreement-with-gilead-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 1228
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-3/
            [children] => 
        )

    [ip-ownership.exploitation-results.mpp-license-agreement-with-gilead-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 1143
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.mpp-license-agreement-with-gilead] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 1114
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead/
            [children] => 
        )

    [liability.indemnity.mpp-license-agreement-with-gilead-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1263
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-5/
            [children] => 
        )

)
MPP - Merck, Raltegravir License Agreement
2015
Industry
Multilateral organization
Drug
Commercialization
  • No Issues
MPP - Pfizer, Sutezolid License Agreement
2019
Industry
Multilateral organization
Drug
Commercialization
Array
(
    [access-to-medicines.pricing.mpp-license-agreement-with-pfizer-re-sutezolid] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 1207
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-pfizer-re-sutezolid/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.mpp-license-agreement-with-pfizer-re-sutezolid] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 1207
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-pfizer-re-sutezolid/
            [children] => 
        )

)
MPP - University of Liverpool, Solid Drug Nanoparticle Technology License Agreement
2015
Academic institution
Multilateral organization
Device
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [business-model.royalties-and-payments.mpps-license-agreement-with-university-of-liverpool] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 1117
            [provision_permalink] => https://ghiaa.org/provision_document/mpps-license-agreement-with-university-of-liverpool/
            [children] => 
        )

)
MPP - ViiV, Dolutegravir License Agreement
2016
Industry
Multilateral organization
Drug
Commercialization
Array
(
    [ip-ownership.use-background-ip.mpp-license-agreement-with-viiv-on-dolutegravir-for-adults] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 1123
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-viiv-on-dolutegravir-for-adults/
            [children] => 
        )

    [liability.indemnity.mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1315
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2/
            [children] => 
        )

)
MSD - MPP, Molnupiravir License Agreement
2021
Industry
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.pricing.msd-mpp-molnupiravir-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 3899
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-8/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.msd-mpp-molnupiravir-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 3895
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-4/
            [children] => 
        )

    [business-model.roles-responsibilities.msd-mpp-molnupiravir-license-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3909
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-17/
            [children] => 
        )

    [business-model.royalties-and-payments.msd-mpp-molnupiravir-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3899
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-8/
            [children] => 
        )

    [business-model.supply-purchase-of-products.msd-mpp-molnupiravir-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3898
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-7/
            [children] => 
        )

    [information-sharing.confidentiality.msd-mpp-molnupiravir-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3896
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.msd-mpp-molnupiravir-license-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3908
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-16/
            [children] => 
        )

    [information-sharing.technology-transfer.msd-mpp-molnupiravir-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 3897
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-6/
            [children] => 
        )

    [ip-ownership.ownership-results.msd-mpp-molnupiravir-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 3890
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.msd-mpp-molnupiravir-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3891
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.msd-mpp-molnupiravir-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 3892
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-3/
            [children] => 
        )

    [liability.indemnity.msd-mpp-molnupiravir-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3900
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-9/
            [children] => 
        )

    [liability.insurance.msd-mpp-molnupiravir-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 3901
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-10/
            [children] => 
        )

    [liability.warranties.msd-mpp-molnupiravir-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3903
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-12/
            [children] => 
        )

    [term-and-termination.term-of-agreement.msd-mpp-molnupiravir-license-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3904
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-13/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.msd-mpp-molnupiravir-license-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3906
            [provision_permalink] => https://ghiaa.org/provision_document/msd-mpp-molnupiravir-license-agreement-14/
            [children] => 
        )

)
Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
2020
Government
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 3356
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 3352
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement/
            [children] => 
        )

    [business-model.regulatory-strategy.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3366
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8/
            [children] => 
        )

    [business-model.roles-responsibilities.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3372
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12/
            [children] => 
        )

    [business-model.royalties-and-payments.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3354
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2/
            [children] => 
        )

    [information-sharing.confidentiality.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3364
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7/
            [children] => 
        )

    [information-sharing.publication-of-results.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 3368
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9/
            [children] => 
        )

    [ip-ownership.exploitation-results.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 3360
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 3360
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4/
            [children] => 
        )

    [ip-ownership.ownership-results.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 3360
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4/
            [children] => 
        )

    [ip-ownership.ownership-results.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 3768
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-6/
            [children] => 
        )

    [ip-ownership.protection-results.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3361
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5/
            [children] => 
        )

    [ip-ownership.use-background-ip.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 3360
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4/
            [children] => 
        )

    [liability.indemnity.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3370
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10/
            [children] => 
        )

    [term-and-termination.effect-of-termination.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3356
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3/
            [children] => 
        )

    [term-and-termination.term-of-agreement.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3356
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3356
            [provision_permalink] => https://ghiaa.org/provision_document/natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3/
            [children] => 
        )

)
NIH - GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Government
Industry
Vaccine
Preclinical
Commercialization
Array
(
    [access-to-medicines.territory-access-commitments.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 3414
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8/
            [children] => 
        )

    [business-model.roles-responsibilities.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3418
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12/
            [children] => 
        )

    [business-model.royalties-and-payments.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3410
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4/
            [children] => 
        )

    [business-model.supply-purchase-of-products.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3414
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8/
            [children] => 
        )

    [information-sharing.confidentiality.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3413
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3412
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6/
            [children] => 
        )

    [information-sharing.technology-transfer.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 3409
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3/
            [children] => 
        )

    [ip-ownership.protection-results.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3411
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5/
            [children] => 
        )

    [ip-ownership.use-background-ip.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 3406
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement/
            [children] => 
        )

    [liability.indemnity.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3415
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9/
            [children] => 
        )

    [liability.warranties.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3415
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9/
            [children] => 
        )

    [term-and-termination.effect-of-termination.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3417
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11/
            [children] => 
        )

    [term-and-termination.term-of-agreement.nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3416
            [provision_permalink] => https://ghiaa.org/provision_document/nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10/
            [children] => 
        )

)
NIH - Non-Profit, Model License Agreement Terms
2017
Government
Multilateral organization
Product development partnership
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [ip-ownership.protection-results.nih-model-license-agreement-for-use-by-non-profit-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1168
            [provision_permalink] => https://ghiaa.org/provision_document/nih-model-license-agreement-for-use-by-non-profit-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.nih-model-license-agreement-for-use-by-non-profit] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 1135
            [provision_permalink] => https://ghiaa.org/provision_document/nih-model-license-agreement-for-use-by-non-profit/
            [children] => 
        )

)
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 3808
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 3806
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11/
            [children] => 
        )

    [business-model.regulatory-strategy.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3807
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12/
            [children] => 
        )

    [business-model.roles-responsibilities.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3810
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15/
            [children] => 
        )

    [business-model.royalties-and-payments.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3801
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6/
            [children] => 
        )

    [business-model.supply-purchase-of-products.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3809
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14/
            [children] => 
        )

    [information-sharing.confidentiality.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3799
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4661
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16/
            [children] => 
        )

    [information-sharing.technology-transfer.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 3800
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 3797
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-results.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 3797
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2/
            [children] => 
        )

    [ip-ownership.protection-results.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3798
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3/
            [children] => 
        )

    [ip-ownership.use-background-ip.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 3796
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement/
            [children] => 
        )

    [liability.indemnity.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3802
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7/
            [children] => 
        )

    [liability.insurance.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 3803
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8/
            [children] => 
        )

    [liability.warranties.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3812
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17/
            [children] => 
        )

    [term-and-termination.effect-of-termination.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3805
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3804
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3804
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9/
            [children] => 
        )

)
Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [business-model.regulatory-strategy.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 4054
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20/
            [children] => 
        )

    [business-model.roles-responsibilities.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4051
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17/
            [children] => 
        )

    [business-model.royalties-and-payments.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4040
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8/
            [children] => 
        )

    [business-model.supply-purchase-of-products.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 4041
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9/
            [children] => 
        )

    [information-sharing.confidentiality.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4032
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4036
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5/
            [children] => 
        )

    [information-sharing.publication-of-results.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 4035
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4/
            [children] => 
        )

    [information-sharing.technology-transfer.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 4038
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7/
            [children] => 
        )

    [ip-ownership.exploitation-results.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 4029
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 4028
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 4028
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement/
            [children] => 
        )

    [ip-ownership.use-background-ip.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 4029
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2/
            [children] => 
        )

    [liability.indemnity.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4042
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10/
            [children] => 
        )

    [liability.insurance.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4043
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11/
            [children] => 
        )

    [liability.warranties.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4045
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13/
            [children] => 
        )

    [term-and-termination.effect-of-termination.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4050
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16/
            [children] => 
        )

    [term-and-termination.term-of-agreement.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4046
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4047
            [provision_permalink] => https://ghiaa.org/provision_document/ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15/
            [children] => 
        )

)
PATH - Aridis, Rotavirus Vaccine Development Agreement
2007
Industry
Product development partnership
Vaccine
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.equitable-access.path-aridis-rotavirus-vaccine-development-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4060
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement/
            [children] => 
        )

    [access-to-medicines.pricing.aridis-path-vaccine-formulation-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 1190
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-2/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.aridis-path-vaccine-formulation-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 1190
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-2/
            [children] => 
        )

    [business-model.roles-responsibilities.path-aridis-rotavirus-vaccine-development-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4061
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-2/
            [children] => 
        )

    [business-model.royalties-and-payments.path-aridis-rotavirus-vaccine-development-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 4063
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-4/
            [children] => 
        )

    [information-sharing.confidentiality.aridis-path-vaccine-formulation-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1240
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.path-aridis-rotavirus-vaccine-development-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4062
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-3/
            [children] => 
        )

    [information-sharing.publication-of-results.path-aridis-rotavirus-vaccine-development-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 4066
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-7/
            [children] => 
        )

    [ip-ownership.exploitation-results.aridis-path-vaccine-formulation-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 1176
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.aridis-path-vaccine-formulation-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 1160
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-8/
            [children] => 
        )

    [ip-ownership.protection-results.aridis-path-vaccine-formulation-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1160
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-8/
            [children] => 
        )

    [ip-ownership.use-background-ip.aridis-path-vaccine-formulation-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 1176
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement/
            [children] => 
        )

    [liability.indemnity.aridis-path-vaccine-formulation-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1275
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-5/
            [children] => 
        )

    [liability.insurance.path-aridis-rotavirus-vaccine-development-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4065
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-6/
            [children] => 
        )

    [liability.warranties.path-aridis-rotavirus-vaccine-development-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4064
            [provision_permalink] => https://ghiaa.org/provision_document/path-aridis-rotavirus-vaccine-development-agreement-5/
            [children] => 
        )

    [term-and-termination.effect-of-termination.aridis-path-vaccine-formulation-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 1283
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-6/
            [children] => 
        )

    [term-and-termination.term-of-agreement.aridis-path-vaccine-formulation-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1283
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-6/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.aridis-path-vaccine-formulation-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1283
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-6/
            [children] => 
        )

)
Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [business-model.regulatory-strategy.pfizer-peru-covid-19-vaccine-binding-term-sheet-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3216
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-2/
            [children] => 
        )

    [business-model.roles-responsibilities.pfizer-peru-covid-19-vaccine-binding-term-sheet-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3220
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-6/
            [children] => 
        )

    [business-model.supply-purchase-of-products.pfizer-peru-covid-19-vaccine-binding-term-sheet-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3217
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-3/
            [children] => 
        )

    [information-sharing.confidentiality.pfizer-peru-covid-19-vaccine-binding-term-sheet-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3218
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.pfizer-peru-covid-19-vaccine-binding-term-sheet-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 3221
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-7/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.pfizer-peru-covid-19-vaccine-binding-term-sheet] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 3215
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet/
            [children] => 
        )

    [liability.indemnity.pfizer-peru-covid-19-vaccine-binding-term-sheet-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3219
            [provision_permalink] => https://ghiaa.org/provision_document/pfizer-peru-covid-19-vaccine-binding-term-sheet-5/
            [children] => 
        )

)
Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
2020
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [information-sharing.technology-transfer.sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 2426
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3/
            [children] => 
        )

    [ip-ownership.ownership-results.sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 2424
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2/
            [children] => 
        )

)
UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Vaccine
Commercialization
Array
(
    [access-to-medicines.donation.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 271
            [slug] => donation
            [title] => Donation
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Donation
            [provision_id] => 2964
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7/
            [children] => 
        )

    [business-model.regulatory-strategy.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 2965
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10/
            [children] => 
        )

    [business-model.royalties-and-payments.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 2947
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9/
            [children] => 
        )

    [business-model.supply-purchase-of-products.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 2949
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5/
            [children] => 
        )

    [information-sharing.confidentiality.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 2956
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 2945
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222/
            [children] => 
        )

    [ip-ownership.ownership-results.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 2945
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222/
            [children] => 
        )

    [liability.indemnity.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 2957
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4/
            [children] => 
        )

    [liability.warranties.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2958
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6/
            [children] => 
        )

    [term-and-termination.effect-of-termination.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 2962
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3/
            [children] => 
        )

    [term-and-termination.term-of-agreement.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 2960
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 2961
            [provision_permalink] => https://ghiaa.org/provision_document/astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11/
            [children] => 
        )

)
UK Secretary of State - Roche, REGN-COV2 Supply Agreement
2021
Government
Industry
Drug
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.donation.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 271
            [slug] => donation
            [title] => Donation
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Donation
            [provision_id] => 3304
            [provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2/
            [children] => 
        )

    [business-model.regulatory-strategy.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3305
            [provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-3/
            [children] => 
        )

    [business-model.roles-responsibilities.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3303
            [provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes/
            [children] => 
        )

    [business-model.royalties-and-payments.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3312
            [provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-9/
            [children] => 
        )

    [business-model.supply-purchase-of-products.3302] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3302
            [provision_permalink] => https://ghiaa.org/provision_document/3302/
            [children] => 
        )

    [information-sharing.confidentiality.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3310
            [provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-7/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 3309
            [provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-6/
            [children] => 
        )

    [ip-ownership.ownership-results.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 3309
            [provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-6/
            [children] => 
        )

    [liability.warranties.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3308
            [provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-5/
            [children] => 
        )

    [term-and-termination.term-of-agreement.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3307
            [provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-4/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3307
            [provision_permalink] => https://ghiaa.org/provision_document/uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-4/
            [children] => 
        )

)
University of Washington - Medicines Patent Pool, Long-acting Injectable HIV Treatment License Agreement
2021
Academic institution
Multilateral organization
Drug
Preclinical
Array
(
    [access-to-medicines.equitable-access.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 4077
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4/
            [children] => 
        )

    [access-to-medicines.pricing.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 4077
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4/
            [children] => 
        )

    [access-to-medicines.territory-access-commitments.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 282
            [slug] => territory-access-commitments
            [title] => Territory access commitments
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Territory access commitments
            [provision_id] => 4077
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4/
            [children] => 
        )

    [business-model.regulatory-strategy.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 4089
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-15/
            [children] => 
        )

    [business-model.roles-responsibilities.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 4079
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6/
            [children] => 
        )

    [business-model.supply-purchase-of-products.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 4080
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-7/
            [children] => 
        )

    [information-sharing.confidentiality.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 4078
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-5/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 4079
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6/
            [children] => 
        )

    [information-sharing.technology-transfer.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Technology transfer
            [provision_id] => 4079
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-6/
            [children] => 
        )

    [ip-ownership.exploitation-results.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 4076
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 4072
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 4076
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-3/
            [children] => 
        )

    [ip-ownership.protection-results.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 4075
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 4072
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement/
            [children] => 
        )

    [liability.indemnity.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 4081
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-8/
            [children] => 
        )

    [liability.insurance.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 4082
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-9/
            [children] => 
        )

    [liability.warranties.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 4085
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-11/
            [children] => 
        )

    [term-and-termination.effect-of-termination.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 4086
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12/
            [children] => 
        )

    [term-and-termination.term-of-agreement.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 4086
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 4086
            [provision_permalink] => https://ghiaa.org/provision_document/university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-12/
            [children] => 
        )

)
US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
2020
Government
Industry
Drug
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.ati-regeneron-covid-19-antibodies-manufacturing-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 3765
            [provision_permalink] => https://ghiaa.org/provision_document/ati-regeneron-covid-19-antibodies-manufacturing-agreement-2/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 2823
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5/
            [children] => 
        )

    [business-model.regulatory-strategy.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 2822
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4/
            [children] => 
        )

    [business-model.royalties-and-payments.ati-regeneron-covid-19-antibodies-manufacturing-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3696
            [provision_permalink] => https://ghiaa.org/provision_document/ati-regeneron-covid-19-antibodies-manufacturing-agreement/
            [children] => 
        )

    [business-model.supply-purchase-of-products.ati-regeneron-covid-19-antibodies-manufacturing-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3696
            [provision_permalink] => https://ghiaa.org/provision_document/ati-regeneron-covid-19-antibodies-manufacturing-agreement/
            [children] => 
        )

    [ip-ownership.exploitation-results.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 2820
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2/
            [children] => 
        )

    [ip-ownership.ownership-results.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 2820
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2/
            [children] => 
        )

    [ip-ownership.protection-results.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 2820
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 2820
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2/
            [children] => 
        )

    [liability.indemnity.regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 2824
            [provision_permalink] => https://ghiaa.org/provision_document/regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6/
            [children] => 
        )

)
US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
2020
Government
Industry
Vaccine
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 3782
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Preparedness & response
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Preparedness & response
            [provision_id] => 3785
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-6/
            [children] => 
        )

    [access-to-medicines.pricing.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Affordable pricing
            [provision_id] => 3786
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7/
            [children] => 
        )

    [business-model.regulatory-strategy.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 3781
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2/
            [children] => 
        )

    [business-model.roles-responsibilities.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 3792
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12/
            [children] => 
        )

    [business-model.royalties-and-payments.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 3786
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7/
            [children] => 
        )

    [business-model.supply-purchase-of-products.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3786
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7/
            [children] => 
        )

    [information-sharing.confidentiality.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 3784
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5/
            [children] => 
        )

    [information-sharing.publication-of-results.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 3783
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4/
            [children] => 
        )

    [ip-ownership.exploitation-results.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 3778
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 3778
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 3778
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 3778
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement/
            [children] => 
        )

    [ip-ownership.use-background-ip.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 3778
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement/
            [children] => 
        )

    [liability.indemnity.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 3789
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9/
            [children] => 
        )

    [liability.warranties.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 3788
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 3791
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11/
            [children] => 
        )

    [term-and-termination.term-of-agreement.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 3791
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 3791
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11/
            [children] => 
        )

)
US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [access-to-medicines.ensuring-continuity.moderna-dod-supply-agreement-for-mrna-vaccine-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 2452
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine-4/
            [children] => 
        )

    [business-model.regulatory-strategy.moderna-dod-supply-agreement-for-mrna-vaccine-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 2449
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine-2/
            [children] => 
        )

    [business-model.supply-purchase-of-products.dod-moderna-covid-19-vaccine-supply-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 268
            [slug] => supply-purchase-of-products
            [title] => Product supply
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Product supply
            [provision_id] => 3495
            [provision_permalink] => https://ghiaa.org/provision_document/dod-moderna-covid-19-vaccine-supply-agreement/
            [children] => 
        )

    [information-sharing.confidentiality.moderna-dod-supply-agreement-for-mrna-vaccine] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 2448
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine/
            [children] => 
        )

    [ip-ownership.exploitation-results.moderna-dod-supply-agreement-for-mrna-vaccine-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 2454
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine-5/
            [children] => 
        )

    [ip-ownership.use-background-ip.moderna-dod-supply-agreement-for-mrna-vaccine-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 2454
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine-5/
            [children] => 
        )

    [liability.indemnity.moderna-dod-supply-agreement-for-mrna-vaccine-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 2450
            [provision_permalink] => https://ghiaa.org/provision_document/moderna-dod-supply-agreement-for-mrna-vaccine-3/
            [children] => 
        )

)
US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Array
(
    [access-to-medicines.ensuring-continuity.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 2739
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6/
            [children] => 
        )

    [business-model.regulatory-strategy.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 2737
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4/
            [children] => 
        )

    [information-sharing.publication-of-results.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 2741
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7/
            [children] => 
        )

    [ip-ownership.exploitation-results.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 2736
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 2734
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine/
            [children] => 
        )

    [ip-ownership.ownership-results.us-department-of-defense-novavax-covid-19-vaccine-development-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 3769
            [provision_permalink] => https://ghiaa.org/provision_document/us-department-of-defense-novavax-covid-19-vaccine-development-agreement/
            [children] => 
        )

    [ip-ownership.use-background-ip.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Use of background IP
            [provision_id] => 2736
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3/
            [children] => 
        )

    [liability.indemnity.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 2743
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9/
            [children] => 
        )

    [liability.warranties.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Representations & Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Representations & Warranties
            [provision_id] => 2742
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effects of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effects of termination
            [provision_id] => 2744
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12/
            [children] => 
        )

    [term-and-termination.term-of-agreement.2748] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 2748
            [provision_permalink] => https://ghiaa.org/provision_document/2748/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 2749
            [provision_permalink] => https://ghiaa.org/provision_document/novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11/
            [children] => 
        )

)
US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.ensuring-continuity.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 281
            [slug] => ensuring-continuity
            [title] => Ensuring continuity
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Ensuring continuity
            [provision_id] => 2466
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2/
            [children] => 
        )

    [business-model.regulatory-strategy.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 56
            [slug] => regulatory-strategy
            [title] => Regulatory strategy
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Regulatory strategy
            [provision_id] => 2463
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5/
            [children] => 
        )

    [business-model.roles-responsibilities.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development] => GHIAA2019\IssueItem Object
        (
            [ID] => 278
            [slug] => roles-responsibilities
            [title] => Governance
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Governance
            [provision_id] => 2467
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development/
            [children] => 
        )

    [business-model.royalties-and-payments.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Payment Structures
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Payment Structures
            [provision_id] => 2457
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10/
            [children] => 
        )

    [information-sharing.confidentiality.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 2464
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4/
            [children] => 
        )

    [information-sharing.publication-of-results.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 2461
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7/
            [children] => 
        )

    [ip-ownership.exploitation-results.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 2462
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6/
            [children] => 
        )

    [liability.indemnity.sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 2465
            [provision_permalink] => https://ghiaa.org/provision_document/sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3/
            [children] => 
        )

)
WHO - Manufacturer, Ebola Products Collaboration LOA Template
2015
Multilateral organization
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [information-sharing.confidentiality.ebola-who-manufacturer-loa-annex] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1227
            [provision_permalink] => https://ghiaa.org/provision_document/ebola-who-manufacturer-loa-annex/
            [children] => 
        )

)
WHO Confidential Disclosure Agreement Template
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.who-mutual-confidential-disclosure-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1247
            [provision_permalink] => https://ghiaa.org/provision_document/who-mutual-confidential-disclosure-agreement/
            [children] => 
        )

)
WHO Project Collaboration Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
  • No Issues
WHO Standard Framework MoU
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.equitable-access.who-standard-framework-memorandum-of-understanding] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Access plans & principles
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Equitable Access
            [display_title] => Equitable Access | Access plans & principles
            [provision_id] => 1156
            [provision_permalink] => https://ghiaa.org/provision_document/who-standard-framework-memorandum-of-understanding/
            [children] => 
        )

    [ip-ownership.ownership-results.who-standard-framework-memorandum-of-understanding] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 1156
            [provision_permalink] => https://ghiaa.org/provision_document/who-standard-framework-memorandum-of-understanding/
            [children] => 
        )

    [liability.indemnity.who-standard-framework-memorandum-of-understanding-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1271
            [provision_permalink] => https://ghiaa.org/provision_document/who-standard-framework-memorandum-of-understanding-2/
            [children] => 
        )

)
WHO Template Collaboration Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.information-sharing-information-sharing.who-template-material-transfer-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Information sharing
            [provision_id] => 1226
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement-3/
            [children] => 
        )

    [information-sharing.publication-of-results.who-template-material-transfer-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 290
            [slug] => publication-of-results
            [title] => Publication of Results
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Publication of Results
            [provision_id] => 1226
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement-3/
            [children] => 
        )

    [ip-ownership.exploitation-results.template-collaboration-agreement-with-who] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Exploitation of results
            [provision_id] => 1155
            [provision_permalink] => https://ghiaa.org/provision_document/template-collaboration-agreement-with-who/
            [children] => 
        )

    [ip-ownership.ownership-results.template-collaboration-agreement-with-who] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of results
            [provision_id] => 1155
            [provision_permalink] => https://ghiaa.org/provision_document/template-collaboration-agreement-with-who/
            [children] => 
        )

    [liability.insurance.who-template-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 2972
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-collaboration-agreement/
            [children] => 
        )

)
WHO Template Material Transfer Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.who-template-material-transfer-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Protecting & sharing information
            [display_title] => Protecting & sharing information | Confidentiality
            [provision_id] => 1225
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.who-template-material-transfer-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Ownership of background IP
            [provision_id] => 1108
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement/
            [children] => 
        )

    [ip-ownership.protection-results.who-template-material-transfer-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => Intellectual Property
            [display_title] => Intellectual Property | Protection of IP
            [provision_id] => 1108
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement/
            [children] => 
        )

    [liability.indemnity.who-template-material-transfer-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnification & liability
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnification & liability
            [provision_id] => 1265
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement-6/
            [children] => 
        )

)